1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,206 | 0,218 | 11.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Fifteen Years Alongside Europe's Drug Discovery Teams: Viva Biotech Strengthens Continuity from Discovery to Development and Manufacturing | 506 | PR Newswire | Delivering Continuity in a Changing LandscapeClients across the region view Viva Biotech not just as a service provider, but as a consistent, reliable partner and collaborator, an extension of their... ► Artikel lesen | |
| 31.03. | Viva Biotech to Present Two Preclinical Pipeline Research Results at AACR Annual Meeting | 1 | AASTOCKS | ||
| 30.03. | Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up | 286 | PR Newswire | CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading AdvantagesThroughout 2025, revenue from the Company's CRO business rose from RMB810.9 million... ► Artikel lesen | |
| 30.03. | Viva Biotech Holdings Full Year Profit Climbs | 1 | RTTNews | ||
| 30.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 18.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 17.03. | Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA | 437 | PR Newswire | SHANGHAI, March 17, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting... ► Artikel lesen | |
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 16.02. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 16.02. | VIVA BIOTECH (01873): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 29.01. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT APPROVAL OF ENVIRONMENTAL IMPACT REPORT FOR LANGHUA PHARMACEUTICAL | 1 | HKEx | ||
| 05.01. | VIVA BIOTECH (01873): UPDATE ANNOUNCEMENT REGARDING DEEMED DISPOSAL AND DISPOSAL OF EQUITY INTEREST IN VIVA SHANGHAI | - | HKEx | ||
| 29.12.25 | Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities | 325 | PR Newswire | SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader... ► Artikel lesen | |
| 15.12.25 | Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. | 461 | PR Newswire | STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which... ► Artikel lesen | |
| 02.12.25 | VIVA BIOTECH (01873): GRANT OF SHARE OPTIONS | 5 | HKEx | ||
| 29.09.25 | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 358 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| 02.09.25 | Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights | 320 | PR Newswire | SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge... ► Artikel lesen | |
| 28.08.25 | Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth | 483 | PR Newswire | Financial Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage... ► Artikel lesen | |
| 15.05.25 | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 437 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| NOVONESIS | 50,86 | -0,20 % | Novonesis To Acquire Thailand Production Facility For Around $50 Mln | WASHINGTON (dpa-AFX) - Novozymes A/S, Novonesis (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B), a biotechnology company, on Wednesday announced an agreement to acquire a production facility... ► Artikel lesen | |
| GENMAB | 238,20 | -0,46 % | Passing of Genmab A/S' Annual General Meeting | Company Announcement At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,570 | +0,85 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 266,00 | +0,76 % | BeOne wins China approval for Amgen's lung cancer drug Imdelltra | ||
| SINO BIOPHARM | 0,630 | -0,74 % | SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE II CLINICAL TRIAL OF KYLO-11 "LPA SIRNA" IN THE ... | ||
| VERICEL | 28,800 | 0,00 % | Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results | Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,334 | -1,18 % | Dünger-Desaster: Lieferketten-Kollaps bedroht Bayer, Nestlé, MustGrow und K+S! Wo liegt die Mega-Chance für Investoren? | Die Eskalation um den Iran hat globale Lieferketten und den Dünger- und Lebensmittelsektor in einen Ausnahmezustand versetzt, da Sanktionen und Sicherheitsrisiken den Export wichtiger Rohstoffe lahmlegen.... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,640 | +3,94 % | Moleculin Biotech, Inc.: Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile | ||
| SENSEI BIOTHERAPEUTICS | 29,700 | -3,26 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| ZAI LAB LTD ADR | 17,600 | -0,56 % | ZAI LAB (09688): GRANT OF SHARE OPTIONS, RESTRICTED SHARE UNITS AND PERFORMANCE SHARE UNITS | ||
| BIOXCEL THERAPEUTICS | 0,928 | +2,20 % | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of... ► Artikel lesen | |
| REGENXBIO | 7,542 | +0,45 % | REGENXBIO Inc.: Regenxbio Reports New Positive Interim Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne
Pivotal dose participants exceeded external controls across... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,160 | +0,99 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| AKEBIA | 1,177 | -1,09 % | H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,006 (-2,80 %) liegt der Kurs bei 0,208 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.